Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.

doi:10.1016/s0920-9964(98)00038-3

Back to search

Article

Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.

Schizophrenia research - 27 Jul 1998

Kapitany T, Meszaros K, Lenzinger E, Schindler S D, Barnas C, Fuchs K, Sieghart W, Aschauer H N, Kasper S

Abstract excerpt

In the present study, the occurrence of tardive dyskinesia (TD) in chronic schizophrenia patients was investigated in relation to pharmacogenetic polymorphisms. It is known that the metabolism of important neuroleptic drugs is influenced by polymorphisms of the CYP2D6 gene, which encodes the cyto...

Topics

Adult
Alleles
Antipsychotic Agents
Cytochrome P-450 CYP2D6
Dyskinesia, Drug-Induced
Female
Genotype
Humans
Male
Polymorphism, Genetic
Schizophrenia

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.